CompletedNCT03748446
Inhaled Xenon for Depression in Bipolarity or Major Depression
About this title
Read the official source — NCT03748446This study assessed depression symptoms.
Medication studyAges 18–65United States
Understand this study
What did researchers investigate?
This study assessed depression symptoms.
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- BostonSee all locations and recruitment
- Study phase
- Early phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
Study information
Study start dateStarted: December 5, 2019
- Recruitment status
- Completed
- Enrollment listed in the registry
- 13
- Sponsor
- Massachusetts General Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Early Phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT03748446
- Official title
Show the full official title
Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Boston
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study assessed depression symptoms.
Who is behind this study?
The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Xenon and Nitrogen gas.
Who was this study for?
Listed age limits: 18 years to 65 years.
